{"Symbol": "FATE", "AssetType": "Common Stock", "Name": "Fate Therapeutics, Inc", "Description": "Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "3535 General Atomics Court, San Diego, CA, United States, 92121", "FullTimeEmployees": "178", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "3124647168", "EBITDA": "-76343000", "PERatio": "None", "PEGRatio": "0", "BookValue": "5.462", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-1.222", "RevenuePerShareTTM": "0.177", "ProfitMargin": "0", "OperatingMarginTTM": "-9.0376", "ReturnOnAssetsTTM": "-0.1749", "ReturnOnEquityTTM": "-0.3873", "RevenueTTM": "13211000", "GrossProfitTTM": "-77090000", "DilutedEPSTTM": "-1.565", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0.94", "AnalystTargetPrice": "39.63", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "195.281", "PriceToBookRatio": "6.347", "EVToRevenue": "193.534", "EVToEBITDA": "0", "Beta": "1.6758", "52WeekHigh": "38.52", "52WeekLow": "13.26", "50DayMovingAverage": "34.0017", "200DayMovingAverage": "30.2841", "SharesOutstanding": "86844000", "SharesFloat": "73126146", "SharesShort": "12378041", "SharesShortPriorMonth": "10994891", "ShortRatio": "19.91", "ShortPercentOutstanding": "0.14", "ShortPercentFloat": "0.1986", "PercentInsiders": "2.066", "PercentInstitutions": "94.682", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}